Literature DB >> 23232091

Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses.

Bartosz Grzymala-Lubanski1, Sara Själander, Henrik Renlund, Peter J Svensson, Anders Själander.   

Abstract

INTRODUCTION: Warfarin treatment with a high time in therapeutic range (TTR) is correlated to fewer complications. The TTR in Sweden is generally high but varies partly depending on local expertise and traditions. A dosing algorithm could minimize variations and increase treatment quality. Here we evaluate the performance of a computerized dosing algorithm.
MATERIALS AND METHODS: 53.779 warfarin treated patients from 125 centers using the Swedish national quality registry AuriculA. If certain criteria are met, the algorithm gives one of seven possible dose suggestions, which can be unchanged, decreased or increased weekly dose by 5, 10 or 15%. The outcome evaluated by the resulting INR value was compared between dose suggestions arising from the algorithm that were accepted and those that were manually changed. There were no randomization, and outcomes were retrospectively analyzed.
RESULTS: Both the algorithm-based and the manually changed doses had worse outcome if only two instead of three previous INR values were available. The algorithm suggestions were superior to manual dosing regarding percent samples within the target range 2-3 (hit-rate) or deviation from INR 2.5 (mean error). Of the seven possible outcomes from the algorithm, six were significantly superior and one equal to the manually changed doses when three previous INR:s were present.
CONCLUSIONS: The algorithm-based dosing suggestions show better outcome in most cases. This can make dosing of warfarin easier and more efficient. There are however cases where manual dosing fares better. Here the algorithm will be improved to further enhance its dosing performance in the future.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23232091     DOI: 10.1016/j.thromres.2012.11.016

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

Review 1.  Optimizing quality care for the oral vitamin K antagonists (VKAs).

Authors:  Vittorio Pengo; Gentian Denas
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Patient compliance with an anticoagulation management system based on a smartphone application.

Authors:  Yetao Li; Li Dong; Daokang Xiang; Yongchun Zhang; Xinbu Chen; Juan Long; Xiulun Liu; Hailin Li; Yile Yi; Yongfeng Fan; Qihua Gong; Min Luo
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

3.  Warfarin Dosing Algorithms and the Need for Human Intervention.

Authors:  Scott E Kasner; Le Wang; Benjamin French; Steven R Messé; Jonas Ellenberg; Stephen E Kimmel
Journal:  Am J Med       Date:  2015-11-28       Impact factor: 4.965

4.  Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling.

Authors:  Shweta R Motiwala; Jackie Szymonifka; Arianna Belcher; Rory B Weiner; Aaron L Baggish; Hanna K Gaggin; Anju Bhardwaj; James L Januzzi
Journal:  J Cardiovasc Transl Res       Date:  2013-12-06       Impact factor: 4.132

Review 5.  Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism.

Authors:  Daniel M Witt; Nathan P Clark; Scott Kaatz; Terri Schnurr; Jack E Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

6.  Triple therapy after PCI - Warfarin treatment quality and bleeding risk.

Authors:  Daniel Wadell; Jens Jensen; Erling Englund; Anders Själander
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

7.  Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia.

Authors:  Zelalem Liyew; Abilo Tadesse; Nebiyu Bekele; Tewodros Tsegaye
Journal:  Adv Hematol       Date:  2021-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.